[go: up one dir, main page]

BR0308023A - Forma cristalina de composto, processo para preparar a mesma, processo para preparar um composto, composto, processo para cristilizar o mesmo, e, composição farmacêutica - Google Patents

Forma cristalina de composto, processo para preparar a mesma, processo para preparar um composto, composto, processo para cristilizar o mesmo, e, composição farmacêutica

Info

Publication number
BR0308023A
BR0308023A BR0308023-4A BRPI0308023A BR0308023A BR 0308023 A BR0308023 A BR 0308023A BR PI0308023 A BRPI0308023 A BR PI0308023A BR 0308023 A BR0308023 A BR 0308023A
Authority
BR
Brazil
Prior art keywords
compound
preparing
solvate
trihydrate
occurs
Prior art date
Application number
BR0308023-4A
Other languages
English (en)
Inventor
John Peter Gilday
Anthony Stephen Graham
Bo Ingvar Ymen
Martin Bohlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0308023A publication Critical patent/BR0308023A/pt
Publication of BRPI0308023B1 publication Critical patent/BRPI0308023B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"FORMA CRISTALINA DE COMPOSTO, PROCESSO PARA PREPARAR A MESMA, PROCESSO PARA PREPARAR UM COMPOSTO, COMPOSTO, PROCESSO PARA CRISTALIZAR O MESMO, E, COMPOSIçãO FARMACêUTICA". A invenção refere-se a alguns solvatos cristalinos e hidratos do composto de fórmula (I) que é conhecido inter alia por meio do número de código ZD1839. Particularmente, a invenção refere-se a um primeiro solvato que ocorre na presença de metanol que é designado como Forma 2 ZDI839 solvato MEOH, um segundo solvato que ocorre na presença de dimetil sulfóxido que é designado como Forma 3 ZDI839 solvato DMSO, e um triidrato que ocorre na presença de água que é designado como Forma 5 ZD1839 triidrato. A invenção ainda refere-se a processos para a preparação destes solvatos e o triidrato e para sua conversão de volta ao composto ZDI839, composições farmacêuticas contendo os mesmos e seu uso na fabricação de medicamentos para uso na produção de um efeito anti-proliferativo em animal de sangue quente como o homem.
BRPI0308023-4A 2002-02-26 2003-02-24 Forma cristalina de composto, composto e composição farmacêutica BRPI0308023B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0204392.5 2002-02-26
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0212462.6 2002-05-30
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
PCT/GB2003/000794 WO2003072108A1 (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839

Publications (2)

Publication Number Publication Date
BR0308023A true BR0308023A (pt) 2004-12-28
BRPI0308023B1 BRPI0308023B1 (pt) 2021-07-27

Family

ID=27767099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308023-4A BRPI0308023B1 (pt) 2002-02-26 2003-02-24 Forma cristalina de composto, composto e composição farmacêutica

Country Status (17)

Country Link
US (2) US7612077B2 (pt)
EP (1) EP1480650B1 (pt)
JP (1) JP4836404B2 (pt)
KR (1) KR20040086452A (pt)
CN (1) CN100404032C (pt)
AT (1) ATE465738T1 (pt)
AU (1) AU2003212500B2 (pt)
BR (1) BRPI0308023B1 (pt)
CA (3) CA2477350C (pt)
DE (1) DE60332322D1 (pt)
ES (1) ES2342660T3 (pt)
HK (1) HK1070582A1 (pt)
IL (2) IL163689A0 (pt)
MX (1) MXPA04008330A (pt)
NO (1) NO329618B1 (pt)
NZ (1) NZ534871A (pt)
WO (1) WO2003072108A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1480679B1 (en) * 2002-02-26 2007-05-23 Astrazeneca AB Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
WO2006090413A1 (en) * 2005-02-23 2006-08-31 Natco Pharma Limited Novel crystalline form of gefitinib and a process for its preparation
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
CN101973944B (zh) * 2010-10-14 2012-07-04 江苏先声药物研究有限公司 一种Gefitinib Form 1 晶型的制备方法
AU2011319842B2 (en) 2010-10-29 2014-05-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
LT2642999T (lt) 2010-11-23 2017-01-25 Abbvie Ireland Unlimited Company Gydymo būdai, naudojant selektyviuosius bcl-2 inhibitorius
CN103319422B (zh) * 2012-03-21 2016-05-04 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼晶型及其制备方法
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
CN103896862B (zh) * 2012-12-25 2017-05-10 江苏天士力帝益药业有限公司 一种吉非替尼Form 1晶型的制备方法
CN103896861A (zh) * 2012-12-26 2014-07-02 亚宝药业集团股份有限公司 抗癌化合物zd1839的无定形物及其制备方法
CN103896863B (zh) * 2012-12-26 2017-06-13 亚宝药业集团股份有限公司 抗癌化合物zd1839的晶型及其制备方法
CN103910690A (zh) * 2013-01-06 2014-07-09 上海科胜药物研发有限公司 一种吉非替尼新晶型及其制备方法
CN103102316A (zh) * 2013-01-17 2013-05-15 李彦 ZD1839Form 1晶型的制备方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103360326B (zh) * 2013-04-19 2016-03-30 南京优科生物医药研究有限公司 吉非替尼晶型i的精制方法
US20140357723A1 (en) * 2013-05-29 2014-12-04 Uwe-Bernd Bernd Ross Tricholine Nasal Formulation and Method of Use
KR20150001936A (ko) * 2013-06-28 2015-01-07 제일약품주식회사 게피티닙의 신규한 결정형 및 이의 제조방법
WO2015170345A1 (en) 2014-05-09 2015-11-12 Council Of Scientific & Industrial Research Pharmaceutical cocrystals of gefitinib
CN107106481A (zh) * 2014-08-28 2017-08-29 通用医疗公司 可注射的浆料及其制造和使用方法
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
CN104277005A (zh) * 2014-09-19 2015-01-14 成都新恒创药业有限公司 一种吉非替尼Form 1晶型的制备方法
EP3233064A1 (en) 2014-12-19 2017-10-25 Synthon BV Pharmaceutical composition comprising gefifinib
WO2017114735A1 (en) * 2015-12-30 2017-07-06 Synthon B.V. Process for making crystalline form a of gefitinib
SG11201807138XA (en) 2016-02-26 2018-09-27 Massachusetts Gen Hospital Medical ice slurry production and delivery systems and methods
CN106083739B (zh) * 2016-05-31 2019-05-14 华南理工大学 吉非替尼新晶型及其基于超临界反溶剂技术的制备方法
CN111454221B (zh) * 2020-04-21 2023-01-06 华南理工大学 一种吉非替尼和布美他尼药物共晶体及其制备方法
CN118221595A (zh) * 2020-06-15 2024-06-21 山东新时代药业有限公司 一种吉非替尼的有机酸盐
US11241330B1 (en) 2021-04-02 2022-02-08 Brixton Biosciences, Inc. Apparatus for creation of injectable slurry

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
EP1480679B1 (en) 2002-02-26 2007-05-23 Astrazeneca AB Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative

Also Published As

Publication number Publication date
BRPI0308023B1 (pt) 2021-07-27
JP2005525354A (ja) 2005-08-25
US7612077B2 (en) 2009-11-03
HK1070582A1 (en) 2005-06-24
ATE465738T1 (de) 2010-05-15
JP4836404B2 (ja) 2011-12-14
AU2003212500B2 (en) 2008-01-03
NO329618B1 (no) 2010-11-22
CA2702297C (en) 2014-02-04
US20050209229A1 (en) 2005-09-22
NO20044047L (no) 2004-11-16
EP1480650B1 (en) 2010-04-28
CA2833470A1 (en) 2003-09-04
AU2003212500A1 (en) 2003-09-09
US20100137304A1 (en) 2010-06-03
WO2003072108A1 (en) 2003-09-04
ES2342660T3 (es) 2010-07-12
CA2477350C (en) 2013-02-12
EP1480650A1 (en) 2004-12-01
CA2477350A1 (en) 2003-09-04
IL163689A (en) 2011-10-31
IL163689A0 (en) 2005-12-18
CA2833470C (en) 2016-03-29
MXPA04008330A (es) 2004-11-26
CN1652790A (zh) 2005-08-10
CA2702297A1 (en) 2003-09-04
NZ534871A (en) 2007-05-31
DE60332322D1 (de) 2010-06-10
CN100404032C (zh) 2008-07-23
KR20040086452A (ko) 2004-10-08

Similar Documents

Publication Publication Date Title
BR0308023A (pt) Forma cristalina de composto, processo para preparar a mesma, processo para preparar um composto, composto, processo para cristilizar o mesmo, e, composição farmacêutica
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
BRPI0408506A (pt) processos para isolamento de forma i cristalina de 5-azacitidina
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
ECSP066667A (es) Derivados de ciclohexano espirociclicos
SE0400284D0 (sv) Novel compounds
GT200400133AA (es) Derivados de pirrolo[3,4-c] pirazol, activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. (solicitud fraccionaria no. 1, derivada de la patente no. pi-2004-0133).
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
NO20055688L (no) Organiske forbindelser
UY28700A1 (es) Compuestos
GT200500296A (es) Sintesis asimetrica de derivados del dehidrobenzofurano
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200420541A (en) Crystalline forms
TW200612920A (en) Novel imidazolidine derivatives
GEP20084470B (en) New phenylpyridinylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
HK1057886A1 (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
ATE341552T1 (de) Derivate morphinähnlicher opioidverbindungen
UY29684A1 (es) Derivados de piperidina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
AR052413A1 (es) Nuevos derivados de piridotienopiriidina
WO2009019721A3 (en) Quercetin derivatives as anti-cancer agents
DE60305003D1 (de) Verfahren zur herstellung von synergistischen stabilisatorgemischen
MY138680A (en) N-{4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors
UY26251A1 (es) Forma cristalina iii de la n- (4-(5- dimetilaminonaftalen-1- sulfonilamino) fenil) -3 - hidroxi-2, 2- dimetilpropionamida

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/02/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/02/2023